Rx pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 7,647,469 | 12,732,027 | 19,207,075 | 21,762,569 | 22,680,771 | 23,350,098 | 24,666,210 | 27,574,317 |
| Profit before tax | 53,017 | 333,697 | 1,309,919 | 848,801 | 1,648,899 | 593,879 | 585,766 | 435,265 |
| Net profit | 44,257 | 309,142 | 1,156,863 | 728,378 | 1,495,990 | 516,487 | 505,383 | 369,263 |
| Equity | 942,620 | 1,251,762 | 1,608,625 | 2,337,003 | 3,832,993 | 3,849,480 | 3,354,863 | 3,724,126 |
| Liabilities | 2,393,588 | 76,629 | 309,263 | 153,741 | 969,189 | 1,260,767 | 3,217,287 | 2,765,330 |
| Non-current assets | 1,268,917 | 738,725 | 529,949 | 522,013 | 4,101 | 4,064 | 6,300 | 6,357 |
| Current assets | 2,117,209 | 589,239 | 1,392,673 | 1,996,544 | 4,798,144 | 5,102,887 | 6,601,011 | 6,467,807 |
| Total assets | 3,386,126 | 1,327,964 | 1,922,622 | 2,518,557 | 4,802,245 | 5,106,951 | 6,607,311 | 6,474,164 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 943,749 | 1,168,007 | 1,169,247 |
| Social insurance contributions | - | - | - | - | - | 62,145 | 41,288 | 38,224 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -34.4% | +66.5% | +50.9% | +13.3% | +4.2% | +3.0% | +5.6% | +11.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.3% | 23.3% | 60.2% | 28.9% | 31.2% | 10.1% | 7.6% | 5.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 4.7% | 24.7% | 71.9% | 31.2% | 39.0% | 13.4% | 15.1% | 9.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.6% | 2.4% | 6.0% | 3.3% | 6.6% | 2.2% | 2.0% | 1.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 0.7% | 2.6% | 6.8% | 3.9% | 7.3% | 2.5% | 2.4% | 1.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.5 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 1.0 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,079,648 | 1,756,142 | 2,680,045 | 3,108,938 | 3,240,110 | 3,113,346 | 3,482,305 | 3,939,188 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Rx pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-05-04 | 2025-05-05 | 1.07 |
| 2025-04-24 | 2025-04-29 | 1.07 |
| 2025-02-18 | 2025-02-18 | 2763.89 |
| 2021-10-05 | 2021-10-05 | 0.01 |
Rx pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-04 | 2025-04-04 | 3545.11 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Rx pharma, UAB (code 302248517) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, revenue reached €27.57M, increasing by 11.8% year on year and by 18.1% over two years. Net profit was €369.3K, down from €505.4K in 2024 and €516.5K in 2023, while the profit margin narrowed to 1.3% from 2.0% and 2.2% in the prior years. The company’s balance sheet remained relatively strong, with total assets of €6.47M at the end of 2025, equity of €3.72M and liabilities of €2.77M. Assets were almost entirely short term, with long-term assets of only €6.4K. Compared with 2024, equity increased and liabilities declined, while total assets were broadly stable. For 2025, ROE was 9.9%, ROA 5.7%, debt-to-equity 0.74 and asset turnover 4.26x. Revenue per employee was €3.94M, indicating high operating productivity in the latest year.